A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers is a research paper published in JTO Clinical and Research Reports (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health National Cancer Institute
Grant: P01 CA129243
National Institutes of Health National Cancer Institute
Grant: P30 CA008748
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5R01CA273224-03
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy
National Institutes of Health
Grant: 5P01CA129243-07
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu
National Institutes of Health
Grant: 5R01CA251591-02
Predicting sensitivity and resistance in RET-driven cancers
Fields of Study
Keywords